ANEST IWATA (6381) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
10 Feb, 2026Executive summary
Net sales for FY2025 3Q were ¥39,488 million, down 1.3% year-over-year, with declines in both air energy and coating businesses, while other businesses grew revenue but remained unprofitable due to upfront investments.
Operating profit fell 18.1% year-over-year to ¥3,796 million, impacted by lower sales, decreased gross profit, and higher SG&A expenses.
Profit attributable to owners of parent decreased 5.6% to ¥3,376 million.
The global economy showed resilience, with AI-related demand and moderate recovery in Japan, but small and medium-sized enterprises faced profit pressure from rising labor costs.
Financial highlights
Gross profit for the period was ¥18,437 million, down from ¥18,724 million year-over-year.
Ordinary profit declined 9.2% to ¥5,190 million; comprehensive income dropped 21.2% to ¥3,630 million.
Basic earnings per share for the period was ¥85.76, compared to ¥90.36 in the prior year.
Total assets increased to ¥69,757 million, and net assets rose to ¥53,967 million.
Cost of sales ratio rose to 53.3% (+0.1pt), SG&A expenses ratio increased to 37.1% (+1.9pt).
Outlook and guidance
Full-year forecasts for FY2025 remain unchanged: net sales ¥58,000 million, operating profit ¥5,550 million, ordinary profit ¥6,710 million, net income ¥4,150 million.
Annual dividend forecast is ¥83.00 per share.
Sales promotion measures and cost controls are planned to drive recovery.
Latest events from ANEST IWATA
- Sales and profit fell, but FX gains and cash flow stability kept guidance unchanged.6381
Q2 202628 Nov 2025 - Q1 sales and profits declined, comprehensive income turned negative, but guidance is unchanged.6381
Q1 20268 Aug 2025 - Sales rose but profits fell on margin and forex pressures; outlook and dividend steady.6381
Q2 202413 Jun 2025 - Sales rose but profits fell on higher costs; full-year outlook maintained amid global risks.6381
Q1 202513 Jun 2025 - Sales up, profits down; FY2025 targets higher sales, lower earnings, and a dividend increase.6381
Q4 20256 Jun 2025 - Profit outlook cut as China lags and costs rise, but investment and R&D remain on track.6381
Q3 20255 Jun 2025